Trial-Only Medicare Coverage Proposed For PET Alzheimer’s Scans
This article was originally published in The Gray Sheet
Executive Summary
Beta amyloid positron emission tomography scans to help diagnose dementia would only be covered by Medicare as part of a clinical trial under a proposed national coverage decision. Eli Lilly requested broader coverage for its Amyvid PET imaging agent.
You may also be interested in...
Imaging Groups Disappointed By CMS’ Final Beta Amyloid PET NCD
Agency’s final national coverage determination for beta amyloid positron emission tomography to diagnose dementia confirms that Medicare will cover the procedure only in clinical trials. On the positive side, it may offer a bit more flexibility in trial design.
Alzheimer’s Community Prepares To Challenge CMS PET Proposal
Alzheimer’s researchers are planning to join with industry in a unified response to a Medicare coverage proposal that would, in their view, disastrously constrain use of positron emission tomography, and imaging agents like Eli Lilly’s Amyvid, in the diagnosis and management of Alzheimer’s patients.
Medicare Panel Finds Little Support For Amyloid PET Imaging Changes
MedCAC panel has limited confidence that there is enough evidence to show beta amyloid positron emission tomography imaging of the brain changes health outcomes. The vote does not bode well for the technology’s coverage proposal due in July.